$-0.02
(Market cap
$656 Mln
Revenue (TTM)
$355 Mln
P/E Ratio
112.5
P/B Ratio
3.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
26.5
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$0
-
Face value
--
-
Shares outstanding
145,760,468
10 Years Aggregate
CFO
$163.46 Mln
EBITDA
$126.33 Mln
Net Profit
$53.79 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
MiMedx Group (MDXG)
| -33.2 | 9.6 | 23.0 | -36.3 | -15.2 | -21.1 | -4.6 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
MiMedx Group (MDXG)
| -29.6 | 9.6 | 215.5 | -54.0 | -33.5 | 19.8 | 323.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
MiMedx Group (MDXG)
|
4.5 | 655.9 | 355.2 | 6.2 | 3.4 | 2.6 | 112.5 | 3.1 |
| 82.6 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 259.8 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 360.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 585.9 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.6 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout MiMedx Group (MDXG)
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary... PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia. Read more
-
General Counsel & Chief Administrative Officer
Mr. William F. Hulse IV
-
General Counsel & Chief Administrative Officer
Mr. William F. Hulse IV
-
Headquarters
Marietta, GA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for MiMedx Group (MDXG)
What is the current share price of MiMedx Group Inc (MDXG) Today?
The share price of MiMedx Group Inc (MDXG) is $4.53 (NASDAQ) as of 01-Sep-2026 14:39 EDT. MiMedx Group Inc (MDXG) has given a return of -15.2% in the last 3 years.
What is the current PB & PE ratio of MiMedx Group Inc (MDXG)?
The P/E ratio of MiMedx Group Inc (MDXG) is 112.50 times as on 28-Aug-2026.
The P/B ratio of MiMedx Group Inc (MDXG) is 3.05 times as on 28-Aug-2026, a 41 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
20.87 |
3.95 |
2024 |
33.80 |
7.43 |
2023 |
19.26 |
9.10 |
2022 |
-10.47 |
4.24 |
2021 |
-55.58 |
7.38 |
What is the 52 Week High and Low of MiMedx Group Inc (MDXG)?
The 52-week high and low of MiMedx Group Inc (MDXG) are Rs 7.97 and Rs 3.03 as of 02-Sep-2026.
What is the market cap of MiMedx Group Inc (MDXG)?
MiMedx Group Inc (MDXG) has a market capitalisation of $ 656 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in MiMedx Group Inc (MDXG)?
Before investing in MiMedx Group Inc (MDXG), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.